CYCLERION
Dead / Abandoned — Abandoned — no statement of use filed (as of 17 Apr 2023)
What this means for you
This application is over — abandoned 17 Apr 2023. The name may be available, but check before relying on it — rights can also come from actual use, not only from the register.
Record
- Serial number
- 88202400
- Mark type
- Design + words
- Filed
- 21 Nov 2018
- Published for opposition
- 21 Jan 2020
- Abandoned
- 17 Apr 2023
- Attorney of record
- Anessa Kramer
Goods and services
- Class 005 — Pharmaceuticals: Pharmaceutical preparations for the prevention and treatment of ocular and ophthalmological diseases, respiratory system diseases, gastrointestinal system diseases, endocrine system diseases, cardiovascular system diseases, diseases of metabolism, central nervous system diseases, peripheral nervous system diseases, musculoskeletal system diseases, urinary system diseases, kidney diseases, hematological diseases, reproductive system diseases, integumentary system disease, skin and scalp diseases, immune system diseases, mitochondrial diseases, sleep disorders, fibrotic diseases, endothelial dysfunction, thrombosis, ischemia, pain, inflammation, burns, ulcers and wounds, namely, preparations that stimulate guanylate cyclases (sGC), increase the concentration of nitric oxide (NO), increase the concentration of cyclic guanosine monophosphate (cGMP), upregulate the NO-sGC-cGMP (nitric oxide- soluble guanylate cyclases- cyclic guanosine monophosphate) pathway, or utilize a synergistic interaction of the NO-sGC-cGMP (nitric oxide- soluble guanylate cyclases- cyclic guanosine monophosphate) pathway with a complementary signaling pathway; Pharmaceutical preparations, namely, pharmaceutical preparations and substances for the prevention and treatment of ocular and ophthalmological diseases, respiratory system diseases, gastrointestinal system diseases, endocrine system diseases, cardiovascular system diseases, diseases of metabolism, central nervous system diseases, peripheral nervous system diseases, musculoskeletal system diseases, urinary system diseases, kidney diseases, hematological diseases, reproductive system diseases, integumentary system disease, skin and scalp diseases, immune system diseases, mitochondrial diseases, sleep disorders, fibrotic diseases, endothelial dysfunction, thrombosis, ischemia, pain, inflammation, burns, ulcers and wounds
Owner
- Cyclerion Therapeutics, Inc., Cambridge, MA, US
- Cyclerion Therapeutics, Inc., Cambridge, MA, US
Prosecution history
- 17 Apr 2023 — ABANDONMENT NOTICE E-MAILED - NO USE STATEMENT FILED
- 17 Apr 2023 — ABANDONMENT - NO USE STATEMENT FILED
- 08 Sept 2022 — NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
- 07 Sept 2022 — SOU EXTENSION 5 GRANTED
- 31 Aug 2022 — SOU EXTENSION 5 FILED
- 31 Aug 2022 — SOU TEAS EXTENSION RECEIVED
- 02 Mar 2022 — NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
- 28 Feb 2022 — SOU EXTENSION 4 GRANTED
- 28 Feb 2022 — SOU EXTENSION 4 FILED
- 28 Feb 2022 — SOU TEAS EXTENSION RECEIVED
- 16 Sept 2021 — NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
- 14 Sept 2021 — SOU EXTENSION 3 GRANTED
- 14 Sept 2021 — SOU EXTENSION 3 FILED
- 14 Sept 2021 — SOU TEAS EXTENSION RECEIVED
- 10 Mar 2021 — NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED